SAINTE-FOY, QUEBEC--(MARKET WIRE)--Jul 31, 2007 -- Bioxel Pharma Inc. (CDNX:BIP.V - News), a leading manufacturer and supplier of taxane active pharmaceutical ingredients (API) and developer of targeted oncology drugs, is pleased to announce that the Corporation has submitted a Drug Master File (DMF) to Health Canada for its docetaxel drug. This filing follows closely the registration of Bioxel’s docetaxel with the US Food and Drug Administration (FDA) on June 21, 2007.
